IQVIA raises annual profit forecast on clinical research demand

IQVIA Holdings

28/07/2026 13:42

July 28 (Reuters) - IQVIA Holdings IQV.N raised its annual profit forecast on Tuesday after reporting better-than-expected second-quarter results, driven by strong demand for its healthcare data and analytics services, sending its shares up 11% before the bell.
Here are the details:
IQVIA and other contract research providers have benefited from improving demand as biotech funding recovers and drugmakers increase outsourcing of clinical development, data analytics and safety testing work.
CEO Ari Bousbib said favorable indicators across the segments point to "sustained momentum for the balance of the year and into 2027."
"Against the backdrop of better CRO sentiment (and a higher bar), IQVIA's results came in better across the board," Leerink Partners analysts said. 
The company raised its 2026 revenue forecast to $17.28 billion to $17.48 billion from $17.15 billion to $17.35 billion previously.
IQVIA now expects 2026 adjusted profit of $12.80 to $13.00 per share, compared with its prior forecast of $12.65 to $12.95 per share.
Second-quarter revenue rose 8.7% to $4.37 billion, topping analysts' estimate of $4.30 billion, while adjusted earnings per share of $3.15 exceeded an expectation of $3.03 per share, according to data compiled by LSEG.
Research & Development Solutions revenue, IQVIA's largest segment, increased 8.8% to $2.58 billion from a year ago, above analysts' estimate of $2.50 billion. Commercial Solutions revenue rose 8.6% to $1.79 billion.
Research & Development Solutions reported net new bookings of $3.15 billion, up 19% year-over-year, resulting in a book-to-bill ratio of 1.22x. This metric compares the value of new orders to revenue recognized.

 (Reporting by Sahil Pandey in Bengaluru; Editing by Pooja Desai)
 ((Sahil.Pandey@thomsonreuters.com;))